{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:29:32Z","timestamp":1762432172341,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001721","name":"Rijksuniversiteit Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201806100216"],"award-info":[{"award-number":["201806100216"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016060","name":"Stichting De Cock-Hadders","doi-asserted-by":"publisher","award":["2020-60"],"award-info":[{"award-number":["2020-60"]}],"id":[{"id":"10.13039\/100016060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016997","name":"Noaber Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bbalip.2022.159163","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:41:37Z","timestamp":1650595297000},"page":"159163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition"],"prefix":"10.1016","volume":"1867","author":[{"given":"Rumei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milaine V.","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martijn","family":"Koehorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim","family":"de Blaauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henkjan J.","family":"Verkade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Freark","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbalip.2022.159163_bb0005","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ebiom.2018.08.024","article-title":"Cholangiopathies \u2013 towards a molecular understanding","volume":"35","author":"Tam","year":"2018","journal-title":"EBioMedicine."},{"key":"10.1016\/j.bbalip.2022.159163_bb0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/liv.12680","article-title":"Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"35","author":"Bell","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.bbalip.2022.159163_bb0015","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/ijms17111864","article-title":"Impact of microbes on the pathogenesis of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC)","volume":"17","author":"Mattner","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbalip.2022.159163_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coph.2019.09.006","article-title":"New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases","volume":"49","author":"Lemoinne","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2017.06.020","article-title":"Primary biliary cholangitis: old and novel therapy","volume":"47","author":"Floreani","year":"2018","journal-title":"Eur.J.Intern.Med."},{"key":"10.1016\/j.bbalip.2022.159163_bb0030","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2022.159163_bb0035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.117.246033","article-title":"Farnesoid X receptor agonists obeticholic acid and chenodeoxycholic acid increase bile acid efflux in Sandwich-cultured human hepatocytes: functional evidence and mechanisms","volume":"365","author":"Guo","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbalip.2022.159163_bb0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2022.159163_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105911","article-title":"Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3","volume":"77","author":"Fan","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0055","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep4.1270","article-title":"Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in ldlr-\/-.Leiden mice","volume":"2","author":"Morrison","year":"2018","journal-title":"<sb:contribution><sb:title>Hepatol.<\/sb:title> <\/sb:contribution><sb:host><sb:issue><sb:series><sb:title>Commun.<\/sb:title><\/sb:series><\/sb:issue><\/sb:host>"},{"key":"10.1016\/j.bbalip.2022.159163_bb0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bbalip.2022.159163_bb0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0070","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jcmgh.2020.12.004","article-title":"Cholangiopathy and biliary fibrosis in Cyp2c70-deficient mice are fully reversed by ursodeoxycholic acid","volume":"11","author":"de Boer","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Honda","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159163_bb0080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-2275(20)38331-0","article-title":"Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions","volume":"30","author":"Heuman","year":"1989","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159163_bb0085","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1113\/EP088870","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"105","author":"Percie du Sert","year":"2020","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1194\/jlr.RA119000243","article-title":"A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice","volume":"61","author":"de Boer","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159163_bb0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cmpb.2008.06.010","article-title":"BrightStat.Com: free statistics online","volume":"92","author":"Stricker","year":"2008","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.bbalip.2022.159163_bb0100","first-page":"269","article-title":"Cholangiocyte pathobiology., nature reviews","volume":"16","author":"Banales","year":"2019","journal-title":"Gastroenterol.Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0105","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2010.03.008","article-title":"Modulation of the microenvironment by senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cirrhosis","volume":"53","author":"Sasaki","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0110","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/hep.26993","article-title":"Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis","volume":"59","author":"Tabibian","year":"2014","journal-title":"Hepatology (Baltimore,MD)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100134","article-title":"Low production of 12\u03b1-hydroxylated bile acids prevents hepatic steatosis in Cyp2c70-\/- mice by reducing fat absorption","author":"Li","year":"2021","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159163_bb0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1194\/jlr.RA119000307","article-title":"Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism","volume":"61","author":"Straniero","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2022.159163_bb0135","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO\u2212\u2083 output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology (Baltimore,MD)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0145","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S207277","article-title":"The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des.Dev.Ther."},{"key":"10.1016\/j.bbalip.2022.159163_bb0150","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1161\/ATVBAHA.118.311122","article-title":"Farnesoid X receptor activation by obeticholic acid elevates liver low-density lipoprotein receptor expression by mRNA stabilization and reduces plasma low-density lipoprotein cholesterol in mice","volume":"38","author":"Singh","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/mol.119.118646","article-title":"Obeticholic acid ameliorates valproic acid-induced hepatic steatosis and oxidative stress","volume":"97","author":"Gai","year":"2020","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0160","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/j.gastro.2016.12.037","article-title":"Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice","volume":"152","author":"de Boer","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbalip.2022.159163_bb0165","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","article-title":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","volume":"71","author":"Al-Dury","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2022.159163_bb0170","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology (Baltimore,MD)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0175","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.23831","article-title":"Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism","volume":"52","author":"Brufau","year":"2010","journal-title":"Hepatology (Baltimore,MD)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0180","article-title":"Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis.","volume":"1","author":"Feaver","year":"2016","journal-title":"JCIInsight"},{"key":"10.1016\/j.bbalip.2022.159163_bb0185","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbalip.2022.159163_bb0195","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41598-020-58562-x","article-title":"Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2022.159163_bb0200","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bbalip.2022.159163_bb0210","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0215","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbalip.2022.159163_bb0220","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.bbalip.2022.159163_bb0225","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.28712","article-title":"Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice","volume":"64","author":"Xu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bbalip.2022.159163_bb0230","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2019.09.050","article-title":"Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis","volume":"18","author":"Bowlus","year":"2020","journal-title":"Clin.Gastroenterol.Hepatol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198122000531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198122000531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:12:44Z","timestamp":1761387164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388198122000531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1388198122000531"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2022.159163","relation":{},"ISSN":["1388-1981"],"issn-type":[{"type":"print","value":"1388-1981"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2022.159163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"159163"}}